Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
February 3rd, 2021
Coronary vasomotion disorders represent frequent functional causes of angina in patients with unobstructed coronaries. The underlying mechanism of angina (endotype) in these patients can be determined by a comprehensive invasive diagnostic procedure based on acetylcholine provocation testing followed by Doppler-derived assessment of the coronary flow reserve and microvascular resistance.
Overview
The invasive diagnostic procedure (IDP) is crucial for identifying functional coronary diseases that often cause angina in patients with unobstructed coronary arteries. This comprehensive evaluation assesses both dilatory and constrictive components of coronary vasomotion through intracoronary flow and pressure measurements.
Key Study Components
Area of Science
- Cardiology
- Coronary vasomotion
- Invasive diagnostics
Background
- Coronary vasomotion disorders are common causes of angina.
- Patients may have unobstructed coronary arteries.
- Understanding the underlying mechanisms is essential for treatment.
- The IDP provides insights into coronary flow reserve and microvascular resistance.
Purpose of Study
- To diagnose functional coronary diseases.
- To evaluate treatment options based on diagnostic findings.
- To enhance understanding of coronary vasomotion mechanisms.
Methods Used
- Intracoronary flow and pressure measurements.
- Assessment at rest and during hyperemia.
- Coronary spasm testing.
- Use of heparin during the procedure.
Main Results
- Identification of different subtypes of functional coronary diseases.
- Correlation between subtypes and prognosis.
- Recommendations for tailored treatment strategies.
- Improved diagnostic accuracy through the IDP.
Conclusions
- The IDP is effective in diagnosing coronary vasomotion disorders.
- It aids in determining optimal treatment for patients.
- Further research may enhance understanding of coronary function.
Frequently Asked Questions
Executive Industry Relevance
Invasive diagnostic protocols that combine acetylcholine provocation with adenosine-based flow reserve assessment address a critical gap in the functional evaluation of coronary vasomotor disorders in patients with unobstructed arteries. This dual testing strategy enables precise endotype classification, supporting targeted therapeutic decisions and reducing mechanistic ambiguity in early cardiovascular drug discovery. Standardized, reproducible protocols are essential for multicenter comparability and translational continuity in biopharma R&D pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic de-risking by distinguishing between epicardial and microvascular spasm versus vasodilatory impairment.
- Supports functional target validation through quantitative assessment of coronary vasomotion.
- Facilitates predictive confidence in linking vascular endotypes to therapeutic hypotheses.
Screening & Assay Development
- Provides validated, quantitative readouts (CFR, HMR) for downstream assay development.
- Standardizes spasm and vasodilation testing for reproducibility across sites and studies.
- Enables reliable evaluation of candidate compounds targeting coronary vasomotor function.
Translational & Preclinical Research
- Aligns invasive human diagnostic outputs with preclinical vascular models for translational biomarker development.
- Supports continuity from mechanistic discovery to preclinical validation of vascular-targeted therapies.
- Informs risk-adjusted advancement decisions based on functional vascular phenotyping.
Pipeline & Workflow Integration
This protocol integrates into the discovery-to-preclinical continuum by providing robust functional phenotyping at the interface of target validation and translational research.
- Discovery Biology: Quantitative spasm and vasodilation testing clarify disease mechanisms and de-risk target selection.
- Screening: CFR and HMR outputs enable assay readiness and cross-study comparability.
- Analytics: Standardized ECG and Doppler measurements support statistical comparison of intervention effects.
- Translational Research: Human endotype data guide preclinical model selection and biomarker alignment.
- Enterprise Reuse: Protocol standardization facilitates multicenter studies and portfolio-wide application.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic uncertainty in vascular drug discovery.
- Operational Value: Enhances reproducibility, standardization, and scalability of coronary functional testing.
- Strategic Value: Improves go/no-go decisions and capital allocation by clarifying vascular endotypes.
- Portfolio Impact: Enables risk-adjusted prioritization of vascular-targeted assets.
Implementation Considerations
- Requires expertise in invasive coronary physiology and Doppler/ECG signal interpretation.
- Demands specialized instrumentation for intracoronary pressure and flow measurements.
- Necessitates rigorous cross-team standardization of protocol steps and data capture.
- Adaptation to different vascular beds or animal models may require protocol modification.
- Signal quality and ECG interpretability are critical for reliable diagnostic outputs.
